Panagora Asset Management Inc. Acquires 60,033 Shares of AgeX Therapeutics (NYSE:AGE)

Panagora Asset Management Inc. grew its position in shares of AgeX Therapeutics (NYSE:AGE) by 350.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,167 shares of the company’s stock after purchasing an additional 60,033 shares during the quarter. Panagora Asset Management Inc. owned about 0.21% of AgeX Therapeutics worth $283,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Deutsche Bank AG purchased a new position in AgeX Therapeutics during the 4th quarter worth $37,000. Iowa State Bank bought a new position in AgeX Therapeutics in the second quarter worth $40,000. Beirne Wealth Consulting Services LLC bought a new position in AgeX Therapeutics in the second quarter worth $44,000. Sigma Planning Corp bought a new position in shares of AgeX Therapeutics during the first quarter valued at $139,000. Finally, Price Capital Management Inc. increased its holdings in shares of AgeX Therapeutics by 62.5% during the first quarter. Price Capital Management Inc. now owns 113,973 shares of the company’s stock valued at $461,000 after acquiring an additional 43,851 shares in the last quarter. Hedge funds and other institutional investors own 16.88% of the company’s stock.

Shares of NYSE:AGE traded up $0.01 on Friday, hitting $2.65. 206 shares of the company traded hands, compared to its average volume of 77,104. AgeX Therapeutics has a 52 week low of $1.13 and a 52 week high of $5.95. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.54 and a quick ratio of 2.54. The stock has a 50 day simple moving average of $2.68 and a 200-day simple moving average of $3.54.



AgeX Therapeutics Profile

AgeX Therapeutics, Inc, a biotechnology company, focuses on the development and commercialization of therapeutics for age-related degenerative diseases in the United Stated. The company is developing AGEX-BAT1 and AGEX-VASC1, which are cell-based approaches in the preclinical stage of development to correct metabolic imbalances in aging; and to restore vascular support in ischemic tissues.

Featured Story: How are institutional investors different from individual investors?

Institutional Ownership by Quarter for AgeX Therapeutics (NYSE:AGE)

Receive News & Ratings for AgeX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AgeX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.